KD6005
/ Shanghai Kanda Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 08, 2026
Dual Inflammatory-Humoral Pathway Blockade by KD6005 Suppresses Autoantibody Production and Prevents Target Organ Damage across Autoimmune Disease Models
(ACR Convergence 2026)
- No abstract available
Immunology
April 02, 2026
A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
(clinicaltrials.gov)
- P1 | N=73 | Completed | Sponsor: Shanghai Kanda Biotechnology Co., Ltd. | Recruiting ➔ Completed
Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
February 02, 2024
A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Shanghai Kanda Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
January 19, 2024
A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
(clinicaltrials.gov)
- P1 | N=72 | Not yet recruiting | Sponsor: Shanghai Kanda Biotechnology Co., Ltd.
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
1 to 4
Of
4
Go to page
1